Attenuation of serum laminin concentrations upon treatment of chronic hepatitis

New Zealand Journal of Medical Laboratory Science

Volumn 63, Issue 1, 2009, Pages 12-17

  Parsian, Hadi ^a   Nouri, Mohammad ^a   Soumi, Mohammad Hossein ^a   Rahimipour, Ali ^a   Qujeq, Durdi ^b   Estakhri, Rasoul ^c   Kashifard, Mehrdad ^b   Agcheli, Karim ^d   Majidi, Golarnininar ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic hepatitis; Hepatic fibrosis; Laminin; Treatment

Indexed keywords

ADEFOVIR; AZATHIOPRINE; INTERFERON; LAMININ; PEGINTERFERON; PREDNISOLONE; RIBAVIRIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; NORMAL VALUE; SENSITIVITY AND SPECIFICITY;

EID: 64949125264     PISSN: 11710195     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM, Martin GR. Laminin - a glycoprotein from basement membranes. J Biol Chem 1979; 254: 9933-7.
2. Burgeson RE, Chiquet M, Deutzmann R, Ekblom P, Engel J, Kleinman H, et al. A new nomenclature for the laminins. Matrix Biol 1994; 14: 209-11.
3. Aumailley M, Smyth N. The role of laminins in basement membrane function. J Anat 1998; 193 (Pt 1): 1-21.
4. Kleinman HK, Cannon FB, Laurie GW, Hassell JR, Aumaiiley M, Terranova VP, et al. Biological activities of laminin. J Cell Biochem 1985; 27: 317-25.
5. Kershenobich Stalamininikowitz D, Weissbrod AB. Liver fibrosis and inflammation. A review. Ann Hepatol 2003; 2: 159-63.
6. Mecham RP. Receptors for laminin on mammalian cells. FASEB J 1991; 5: 2538-46.
7. Haas TA, Plow EF. Integrin-ligand interactions: a year in review. Curr Opin Cell Biol 1994; 6: 656-62.
8. Martinez-Hernandez A. The hepatic extracellular matrix. I. Electron immunohistochemical studies in normal rat liver. Lab Invest 1984; 51: 57-74.
9. Parise ER, Summerfield JA, Hahn E, Wiedmann KH, Doenhoff MJ. Basement membrane proteins and type III procollagen in murine schistosomiasis. Trans R Soc Trop Med Hyg 1985; 79: 663-70.
10. Shah KD, Gerber MA. Development of intrahepatic bile ducts in humans. Possible role of laminin. Arch Pathol Lab Med 1990; 114: 597-600.
11. Caron JM. Induction of albumin gene transcription in hepatocytes by extracellular matrix proteins. Mol Cell Biol 1990; 10: 1239-43.
12. Martinez-Hernandez A, Delgado FM, Amenta PS. The extracellular matrix in hepatic regeneration. Localization of collagen types I, III, IV, laminin, and fibronectin. Lab Invest 1991; 64: 157-66. Erratum in: Lab Invest 1991; 65: 257.
13. Gressner AM, Bachem MG. Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis. Semin Liver Dis 1990; 10: 30-46.
14. Schaffner F, Poper H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963; 44: 239-42.
15. Hahn E, Wick G, Pencev D, Timpl R. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut 1980; 21: 63-71.
16. Schneider M, Voss B, Hogemann B, Eberhardt G, Gerlach U. Evaluation of serum laminin P1, procollagen-III peptides, and N-acetyl-beta-glucosaminidase for monitoring the activity of liver fibrosis. Hepatogastroenterology 1989; 36: 506-10.
17. Niemela O, Risteli J, Blake JE, Risteli L, Compton KV, Orrego H. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990; 98: 1612-9.
18. Korner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996; 25: 684-8.
19. Kropf J, Gressner AM, Tittor W. Logistic-regression model for assessing portal hypertension by measuring hyaluronic acid (hyaluronan) and laminin in serum. Clin Chem 1991; 37: 30-5.
20. Forns X, Ampurdanes S, Llovet M, Aponte J, Quinto L, Matinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36 (4 Pt 1):986-92.
21. Alvarez F, Berg PA, Bianchi FB, et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
22. HC Thomas, S Lemon, AJ Zuckerman (Editors). Viral Hepatitis, 3rd Edition. Wiley-Blackwell, USA 2005: 149-553.
23. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
24. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
25. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39; 561-77. Erratum in: Clin Chem 1993; 39: 1589.
26. Huguet J, Castineiras MJ, Fuentes-Arderiu X. Diagnostic accuracy evaluation using ROC curve analysis. Scand J Clin Lab Invest 1993; 53: 693-9.
27. Ponomarenko Y, Leo MA, Kroll W, Lieber CS. Effects of alcohol consumption on eight circulating markers of liver fibrosis. Alcohol Alcohol 2002; 37: 252-5.
28. Annoni G, Colombo M, Cantaluppi MC, Khlat B, Lampertico P, Rojkind M. Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers. Hepatology 1989; 9: 693-7.
29. Gressner AM, Tittor W. Serum laminin - its concentration increases with portal hypertension in cirrhotic liver disease. Klin Wochenschr 1986; 64: 1240-8.
30. Mal F, Hartmann DJ, Trinchet JC, Lacombe F, Ville G, Beaugrand M. [Serum laminin and portal pressure in alcoholic cirrhosis. A study of 39 patients] in French. Gastroenterol Clin Biol 1988; 12: 841-4.
31. Kondo M, Miszputen SJ, Leite-mor MM, Parise ER. The predictive value of serum laminin for the risk of variceal bleeding related to portal pressure concentrations. Hepatogastroenterology 1995; 42: 542-5.
32. Gressner AM, Tittor W, Negwer A. Serum concentrations of N-terminal propeptide of type III procollagen and laminin in the outflow of fibrotic livers compared with liver-distal regions. Hepatogastroenterology 1986; 33: 191-5.
33. Parise ER, Leite-Mor MM, Rosa H. Serum laminin in hepatosplenic human schistosomiasis. Mem Inst Oswaldo Cruz 1992; 87 Suppl 4: 127-8.
34. Lebensztejn DM, Skiba E, Sobaniec-Lotowska ME, Kaczmarski M. Serum hyaluronan and laminin level in children with chronic hepatitis B during long-term lamivudine treatment. Hepatogastroenterology 2007; 54: 834-8.
35. Attallah AM, Toson EA, Shiha GE, Omran MM, Abdel-Aziz MM, El-Dosoky I. Evaluation of serum procollagen aminoterminal propeptide III, laminin, and hydroxyproline as predictors of severe fibrosis in patients with chronic hepatitis C. J Immunoassay Immunochem 2007; 28: 199-211.
36. Santos VN, Leite-Mor MM, Kondo M, Martins JR, Nader H, Lanzoni VP, et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005; 38: 747-53.
37. Castera L, Hartmann DJ, Chapel F, Guettier C, Mall F, Lons T, et al. Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J Hepatol 2000; 32: 412-8.
38. Smedsrod B, Paulsson M, Johansson S. Uptake and degradation in vivo and in vitro of laminin and nidogen by rat liver cells. Biochem J 1989; 261: 37-42.
39. Nouchi N, Worner TM, Sato S, Liebers CS. Serum procollagen Type III N-terminal peptides and laminin P1 peptide in alcoholic liver disease. Alcohol Clin Exp Res 1987; 11: 287-91.